Mechanisms of Action of GLP-1 and GIP

From incretin physiology to GLP-1/GIP receptor agonists

Published

October 17, 2026

Introduction

English version — machine-assisted translation (by generative AI, Anthropic Claude) of the original Japanese hands-on. 日本語版はこちら.

This is lecture material for understanding, step by step, where the two gut hormones (incretins) GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) are made, which receptors they bind to, what happens inside the cell, and what effects they have throughout the body.

In the second half, drugs such as semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound) are organized from the viewpoint of how they overcame the weaknesses of the physiological hormones. Finally, you will use simulations that run in your browser to check for yourself “why once-weekly dosing is enough” and “why these drugs rarely cause hypoglycemia”.

WarningCaution

This material is for educational purposes only. Do not use it for diagnostic or treatment decisions for individual patients; consult the latest package inserts and clinical practice guidelines. Clinical-trial figures are approximate values taken from representative reports.

Intended audience

  • Students and healthcare professionals in medicine, pharmacy, nursing, nutrition, and the life sciences
  • Readers with physiology/biochemistry knowledge at the level of “insulin is released from pancreatic β-cells” and “a GPCR is a cell-membrane receptor”

Learning goals

  1. Explain what the incretin effect is by comparing oral glucose with intravenous glucose
  2. Explain the differences between GLP-1 and GIP in their secreting cells, precursors, and degrading enzyme (DPP-4)
  3. Explain the pathway from the receptor through cAMP → PKA/Epac2 → insulin exocytosis, and why it is glucose-dependent
  4. Explain the similarities and differences between the actions of GLP-1 and GIP in the islets (β-cells, α-cells) and outside the pancreas (brain, stomach, adipose tissue, etc.)
  5. Explain the design rationale of DPP-4 inhibitors, GLP-1 receptor agonists, and GIP/GLP-1 receptor agonists

Chapters

Chapter Content Approx. time
1 What is the incretin effect? 15 min
2 Secretion and degradation: L-cells, K-cells, DPP-4 20 min
3 Receptors and intracellular signaling 25 min
4 Actions in the islets: β-cells and α-cells 20 min
5 Extrapancreatic actions: brain, stomach, fat, cardiovascular 25 min
6 Application to drugs 25 min
7 Hands-on: simulation in the browser 20 min
8 Review questions 20 min
NoteSlide version

The lecture slides with the key points are here. Press F for full screen, S for speaker notes, and Esc for the overview.

The big picture first

Before going into details, here is a map of the whole lecture. Coming back here after reading each chapter will help you see where things fit.

flowchart LR
  Meal["Meal<br/>(sugars, fats)"] --> K["K-cells<br/>duodenum, upper jejunum"]
  Meal --> L["L-cells<br/>ileum, colon"]
  K -->|GIP| Blood(("Blood"))
  L -->|GLP-1| Blood
  Blood -.->|"degraded by DPP-4<br/>within minutes"| X["Inactive form"]
  Blood --> Beta["Pancreatic β-cells<br/>insulin↑<br/>(glucose-dependent)"]
  Blood --> Alpha["Pancreatic α-cells<br/>GLP-1: glucagon↓<br/>GIP: glucagon↑"]
  Blood --> Brain["Brain<br/>appetite↓ (GLP-1)"]
  Blood --> Stomach["Stomach<br/>delayed gastric emptying (GLP-1)"]
  Blood --> Fat["Adipose tissue<br/>lipid uptake (GIP)"]

Glossary

Incretin

Collective term for hormones secreted from the gut that enhance postprandial insulin secretion. Mainly GLP-1 and GIP.

GLP-1

glucagon-like peptide-1. A 30–31-amino-acid peptide derived from proglucagon. Secreted by L-cells.

GIP

glucose-dependent insulinotropic polypeptide (formerly gastric inhibitory polypeptide). 42 amino acids. Secreted by K-cells.

DPP-4

dipeptidyl peptidase-4. An enzyme that cleaves off the two N-terminal residues of peptides whose second residue from the N-terminus is Ala/Pro. It inactivates incretins.

GLP-1R / GIPR

The respective receptors. Both are class B1 G protein-coupled receptors (GPCRs).

RA (receptor agonist)

A drug that activates a receptor. GLP-1RA = GLP-1 receptor agonist.